Skip to main content
A person holding a notebook speaks into a microphone

Industry Liaison Forum

The Industry Liaison Forum was established in 2001 to promote and facilitate the full contribution of the biomedical industry to the global HIV response. It does this by catalysing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum. Its members are from industry (originator and generic biopharmaceutical, diagnostic and other health-technology companies) and non-industry organizations. They share a wealth of perspectives, expertise and knowledge to contribute together to the HIV response.

The Forum’s strategic plan for 2020-2023 highlights its commitment to further build on its unique neutrality, convening power, multi-stakeholder composition and rules of engagement to strengthen its contribution to the HIV response. To achieve this, it:

  • Engages and grows membership by continuing to be a cross-stakeholder, neutral, safe-space platform that actively expands and engages its membership base to foster connections, dialogue and action.
  • Accelerates priority areas by addressing barriers along the HIV prevention, diagnosis and care continuum.
  • Publishes and promotes members’ perspectives to advance the global HIV response.

Interested in joining? Please contact [email protected].

Case Studies

Case study 1: Accelerating access to long-acting HIV prevention and treatment formulations and delivery platforms

In 2022, the Forum, with Medicines Patent Pool (MPP), brought together partners through a three-part roundtable series to drive the conversation on what is needed to accelerate the introduction and scale up of long-acting technologies in low- and middle-income countries. Building on this roundtable series, a satellite session was organized at AIDS 2022 (watch here and find the report here). These discussions led to the official AIDS 2022 press release on breaking news about ViiV and MPP’s voluntary licensing agreement for patents relating to CAB-LA for PrEP. Access the roundtable materials here.

alternative text

Case study 2: WHO Prequalification of In Vitro Diagnostics

In 2018, Forum industry partners published a perspective on World Health Organization (WHO) Prequalification of In Vitro Diagnostics in Clinical Infectious Diseases. In 2022, the Forum coordinated a roundtable discussion with representatives of regulatory and normative agencies, as well as the diagnostics and pharmaceutical industry, to introduce the newly published WHO collaborative procedure. This is a tool for national regulatory authorities that wish to enhance their pre-marketing and post-registration evaluation and registration of in vitro diagnostics. To access the roundtable materials, click here.

alternative text

Case study 3: The GAP-f

The Global Accelerator for Paediatric Formulations (GAP-f) resulted from collaboration between members of the Forum, the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) and WHO. Forum corporate partners working with international stakeholders steered the agenda and efforts to create GAP-f.

alternative text

Case study 4: Policy brief on innovative digital technologies

Forum corporate partners, with international stakeholders, reviewed learnings from the COVID-19 response to recommend a set of innovative technologies that should be scaled up for better HIV prevention and treatment. To read the blog post on this topic, click here.

alternative text

Meet the Forum members

Co-chairs

Nittaya Phanuphak
Nittaya Phanuphak

Nittaya Phanuphak

Institute of HIV Research and Innovation (IHRI)
Thailand
View
Helen McDowell
Helen McDowell

Helen McDowell

Head of Government Affairs & Global Public Health, ViiV Healthcare
United Kingdom
View

Civil Society

Brent Allan
Brent Allan

Brent Allan

Global community engagement consultant
Australia
View
Rahab Mwaniki
Rahab Mwaniki

Rahab Mwaniki

Public Health Specialist and Programme Officer, National Empowerment Network of People Living with HIV/AIDS
Kenya
View
Wim Vandevelde
Wim Vandevelde

Wim Vandevelde

Liaison Officer, GNP+
South Africa
View

Industry

Donna Fromhold
Donna Fromhold

Donna Fromhold

United States
View
Joanna Sickler
Joanna Sickler

Joanna Sickler

United States
View
Beverley Goede
Beverley Goede

Beverley Goede

United States
View
James F Rooney
James F Rooney

James F Rooney

Gilead Sciences
United States
View
Samuel (Tony) Boova
Samuel (Tony) Boova

Samuel (Tony) Boova

United States
View

Non-industry

Boniface Dongmo Nguimfack
Boniface Dongmo Nguimfack

Boniface Dongmo Nguimfack

Technical Lead Access to Medicines and Diagnostics, HIV, Hepatitis and STIs, HTM/HHS/SIA WHO
Switzerland
View
Catherine Hankins
Catherine Hankins

Catherine Hankins

Amsterdam Institute for Global Health and Development (AIGHD)
Netherlands
View
Colleen Daniels
Colleen Daniels

Colleen Daniels

Deputy Director and Public Health Lead, Harm Reduction International
United Kingdom
View
Elliot P Cowan
Elliot P Cowan

Elliot P Cowan

Principal and Founder, Partners in Diagnostics. Chief Regulatory Officer, TestZone
United States
View
Ray Corrin
Ray Corrin

Ray Corrin

Prequalification of Medicines Program, World Health Organization, WHO
Switzerland
View
Teri Roberts
Teri Roberts

Teri Roberts

Elizabeth Glaser Pediatric AIDS Foundation
Switzerland
View
Carmen Pérez Casas
Carmen Pérez Casas

Carmen Pérez Casas

Senior Technical Manager, Strategy, Unitaid
Switzerland
View
Sandeep Juneja
Sandeep Juneja

Sandeep Juneja

Senior Vice President of Market Access, TB Alliance
Switzerland
View

Ex-officio – International AIDS Society

Nelli Barrière
Nelli Barrière

Nelli Barrière

International AIDS Society
View
Adeeba Kamarulzaman
Adeeba Kamarulzaman

Adeeba Kamarulzaman

Immediate Past President
University of Malaya
Malaysia
View
Birgit Poniatowski
Birgit Poniatowski

Birgit Poniatowski

IAS Executive Director
International AIDS Society
Switzerland
View
Carole Beilleau
Carole Beilleau

Carole Beilleau

Director, Development and Partnerships
International AIDS Society
View
Adaora Adimora
Headshot of Adaora Adimora

Adaora Adimora

Division of Infectious Diseases Chapel Hill
United States
View